Although most FISH studies on MET alterations in cancer report either a MET/CEN7 ratio ≥2.0 or an average MET-GCN/cell of at least 4 in a tumor sample for categorizing it as MET-amplified, the parameters used and the cutoff to define “positivity” are not standardized and this may cause differences in the reported frequency of MET-amplification and its ability to be exploited as a potential therapeutic target [5]. The gene discussed is MET; the disease is cancer.